Department of Behavioral Science, University of Kentucky College of Medicine.
Department of Pharmacology and Toxicology, Virginia Commonwealth University Medical Center.
Exp Clin Psychopharmacol. 2020 Apr;28(2):169-180. doi: 10.1037/pha0000302. Epub 2019 Jul 1.
Drug self-administration procedures are the gold standard for laboratory research to study mechanisms of drug use disorders and evaluate candidate medications. However, preclinical-to-clinical translation has been hampered by a lack of coordination. To address this limitation, we previously developed homologous intravenous (IV) cocaine choice self-administration procedures in rhesus monkeys and humans, and then demonstrated their functional equivalence. The present studies sought to determine the sensitivity of these procedures to d-amphetamine maintenance. Three (N = 3) rhesus monkeys with histories of cocaine self-administration and 16 (N = 16) humans with cocaine use disorder completed the studies. Monkeys were maintained on IV d-amphetamine (0, 0.019, 0.037 and 0.074 mg/kg/h), and then completed 7 sessions during each condition in which they completed 9 choice trials to receive 0.14 mg/kg/injection IV cocaine (corresponding to 10 mg/70 kg in humans) or 10 food pellets under independent, concurrent progressive-ratio schedules. Humans were maintained on oral extended release d-amphetamine (0, 30 and 60 mg/day, corresponding to the lowest 3 doses in monkeys) and participated in 12 sessions in which they chose money ($6.00) or IV cocaine (0, 3, 10 and 30 mg/70 kg). Blood samples were taken to compare d-amphetamine plasma levels across species. In monkeys and humans, d-amphetamine reduced the number of cocaine choices and produced comparable blood levels at equivalent daily doses. d-Amphetamine had similar efficacy, though lower potency, at reducing choice for an equivalent cocaine dose in monkeys relative to humans. These coordinated studies support the utility of these procedures as a translational model for cocaine use disorder. (PsycInfo Database Record (c) 2020 APA, all rights reserved).
药物自我给药程序是研究药物使用障碍机制和评估候选药物的实验室研究的金标准。然而,临床前到临床的转化受到缺乏协调的阻碍。为了解决这个限制,我们之前在恒河猴和人类中开发了同源的静脉内(IV)可卡因选择自我给药程序,然后证明了它们的功能等效性。本研究旨在确定这些程序对 d-苯丙胺维持的敏感性。具有可卡因自我给药史的 3 只(N = 3)恒河猴和 16 名(N = 16)可卡因使用障碍患者完成了这些研究。猴子接受 IV d-苯丙胺(0、0.019、0.037 和 0.074 mg/kg/h)维持治疗,然后在每个条件下完成 7 个疗程,在每个疗程中,他们完成 9 个选择试验,以接受 0.14 mg/kg/IV 可卡因(相当于人类中的 10 mg/70 kg)或 10 个食物丸在独立的、同时进行的递增比率方案下。人类接受口服缓释 d-苯丙胺(0、30 和 60 mg/天,相当于猴子中的最低 3 个剂量),并参加了 12 个疗程,他们可以选择金钱($6.00)或 IV 可卡因(0、3、10 和 30 mg/70 kg)。采集血样以比较跨物种的 d-苯丙胺血浆水平。在猴子和人类中,d-苯丙胺减少了可卡因的选择,并在等效的每日剂量下产生了类似的血液水平。d-苯丙胺在减少猴子相对于人类的等效可卡因剂量的选择方面具有相似的疗效,但效力较低。这些协调一致的研究支持这些程序作为可卡因使用障碍的转化模型的效用。(PsycInfo 数据库记录(c)2020 APA,保留所有权利)。